FDA
EMA
MHRA
PMDA
Health Canada

Clinical

Phase I
Phase II
Phase III
Readouts
Enrollment Signals

Competitive

Pipeline Tracking
Company Moves
Asset Intelligence
Landscape Reports

Markets

Pricing
Access
Commercial
Launch Tracking

M&A Watch

Licensing
Acquisitions
Partnerships
Capital Raises

Strategy Catalysts Pricing

Humanexa Signals

Data-driven pharmaceutical intelligence for biotech investors, pharma operators, consultants, and intelligence teams.

Company

Pricing
Partner with us
Subscribe
Contact
Privacy

Subscribe to Humanexa Signals

Weekly intelligence for pharma decision-makers.

No paywall. No spam. Unsubscribe anytime.

Intelligence powered by the Humanexa engine.

Asset / Drug

Ultomiris

Drug and asset intelligence for Ultomiris with 4 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals: 2
Catalysts: 2
Stage: Approved

Sponsor company

AstraZeneca →

Recent signals(2)

ClinicalJuly 28, 2026

Ultomiris Phase III trial fails to meet primary endpoint in HSCT-TMA

Ultomiris did not achieve statistical significance for event-free survival in HSCT-TMA patients compared to placebo.

ClinicalJune 16, 2026

Ultomiris meets primary endpoint in Phase III trial for IgAN

Ultomiris showed a statistically significant reduction of proteinuria in adults with immunoglobulin A nephropathy in the Phase III I CAN trial.

Upcoming milestones

No catalysts indexed for this entity yet.

Related catalysts(2)

Acquisition

Alexion — Ultomiris

Rumor of bolt-on rare disease acquisition to bolster AstraZeneca Alexion unit pipeline.

September 1, 2026 · Approved

Topline Data

AstraZeneca — Ultomiris

June 16, 2026 · N/A

Indications

Generalized myasthenia gravis (pediatric) →

Therapeutic areas

Complement Inhibition →

Hematology →

Nephrology →

Nephrology · Complement Inhibition →

Rare Disease →

Thrombotic Microangiopathy →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.